Medpace (NASDAQ:MEDP) Shares Down 0.6%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price traded down 0.6% during trading on Tuesday . The company traded as low as $395.55 and last traded at $397.98. 30,243 shares were traded during trading, a decline of 88% from the average session volume of 248,001 shares. The stock had previously closed at $400.21.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Guggenheim upped their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price target for the company from $340.00 to $450.00 in a research report on Tuesday, April 23rd. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, Robert W. Baird lifted their target price on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Down 1.7 %

The stock has a market cap of $12.12 billion, a PE ratio of 40.79, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40. The firm has a fifty day moving average of $398.32 and a 200 day moving average of $328.94.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.27 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

Insider Activity

In other Medpace news, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the completion of the transaction, the insider now owns 5,525,959 shares in the company, valued at $2,135,175,298.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, major shareholder Medpace Investors, Llc sold 13,988 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the completion of the sale, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the completion of the sale, the director now directly owns 250 shares of the company’s stock, valued at $102,467.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 204,442 shares of company stock worth $82,702,867. Corporate insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in Medpace by 353.2% in the 3rd quarter. SG Americas Securities LLC now owns 2,515 shares of the company’s stock valued at $609,000 after purchasing an additional 1,960 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Medpace by 20.2% in the third quarter. Commonwealth Equity Services LLC now owns 2,765 shares of the company’s stock valued at $669,000 after purchasing an additional 465 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in Medpace by 13.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 3,755 shares of the company’s stock valued at $909,000 after purchasing an additional 440 shares during the last quarter. FinTrust Capital Advisors LLC purchased a new position in shares of Medpace in the third quarter valued at $30,000. Finally, GW Henssler & Associates Ltd. acquired a new position in shares of Medpace during the 3rd quarter worth $208,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.